Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Another knock back for urea cycle disorders
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
Neuren pays the price for sellside froth
The Australian group has found a partner for its lead asset at last, so why is the stock down?
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
